233 related articles for article (PubMed ID: 26115765)
1. Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy.
Srivastava G; Matta A; Fu G; Somasundaram RT; Datti A; Walfish PG; Ralhan R
Mol Oncol; 2015 Oct; 9(8):1720-35. PubMed ID: 26115765
[TBL] [Abstract][Full Text] [Related]
2. Anticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer Therapy.
Srivastava G; Somasundaram RT; Walfish PG; Ralhan R
PLoS One; 2015; 10(7):e0133735. PubMed ID: 26208303
[TBL] [Abstract][Full Text] [Related]
3. ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.
Fu G; Somasundaram RT; Jessa F; Srivastava G; MacMillan C; Witterick I; Walfish PG; Ralhan R
Oncotarget; 2016 Mar; 7(13):17162-81. PubMed ID: 26934445
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.
Luo Q; Hu D; Hu S; Yan M; Sun Z; Chen F
BMC Cancer; 2012 Nov; 12():517. PubMed ID: 23151022
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
[TBL] [Abstract][Full Text] [Related]
6. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
[TBL] [Abstract][Full Text] [Related]
7. Arglabin is a plant sesquiterpene lactone that exerts potent anticancer effects on human oral squamous cancer cells via mitochondrial apoptosis and downregulation of the mTOR/PI3K/Akt signaling pathway to inhibit tumor growth in vivo.
He W; Lai R; Lin Q; Huang Y; Wang L
J BUON; 2018; 23(6):1679-1685. PubMed ID: 30610794
[TBL] [Abstract][Full Text] [Related]
8. Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy.
Huang KJ; Kuo CH; Chen SH; Lin CY; Lee YR
J Cell Mol Med; 2018 Mar; 22(3):1894-1908. PubMed ID: 29363886
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA CCAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt/β-catenin signaling pathway.
Li GH; Ma ZH; Wang X
Cell Cycle; 2019 Nov; 18(21):2902-2913. PubMed ID: 31599709
[TBL] [Abstract][Full Text] [Related]
10. Tanshinone IIA induces cell death via Beclin-1-dependent autophagy in oral squamous cell carcinoma SCC-9 cell line.
Qiu Y; Li C; Wang Q; Zeng X; Ji P
Cancer Med; 2018 Feb; 7(2):397-407. PubMed ID: 29316373
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor effect of cisplatin in human oral squamous cell carcinoma cells by tumor suppressor GRIM‑19.
Li M; Li Z; Li J; Jin L; Jin C; Han C; Ji X; Sun F
Mol Med Rep; 2015 Dec; 12(6):8185-92. PubMed ID: 26458285
[TBL] [Abstract][Full Text] [Related]
12. Alkannin restrains oral squamous carcinoma cell growth, migration and invasion by regulating microRNA-9/RECK axis.
Mao Y; Zhang W; Zhang R; Zuo J
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3153-3162. PubMed ID: 31349748
[TBL] [Abstract][Full Text] [Related]
13. The in vitro and in vivo antitumor effects of clotrimazole on oral squamous cell carcinoma.
Wang J; Jia L; Kuang Z; Wu T; Hong Y; Chen X; Leung WK; Xia J; Cheng B
PLoS One; 2014; 9(6):e98885. PubMed ID: 24892421
[TBL] [Abstract][Full Text] [Related]
14. Application of a Persistent Heparin Treatment Inhibits the Malignant Potential of Oral Squamous Carcinoma Cells Induced by Tumor Cell-Derived Exosomes.
Sento S; Sasabe E; Yamamoto T
PLoS One; 2016; 11(2):e0148454. PubMed ID: 26849680
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine A Suppresses the Malignant Progression of Oral Squamous Cell Carcinoma in vitro.
Gao L; Dong J; Zhang N; Le Z; Ren W; Li S; Li F; Song J; Wang Q; Dou Z; Park SY; Zhi K
Anticancer Agents Med Chem; 2019; 19(2):248-255. PubMed ID: 30378503
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Yang CY; Tsao CH; Hsieh CC; Lin CK; Lin CS; Li YH; Chang WC; Cheng JC; Lin GJ; Sytwu HK; Wang YL; Chen YW
PLoS One; 2020; 15(7):e0236101. PubMed ID: 32678829
[TBL] [Abstract][Full Text] [Related]
17. Zerumbone targets the CXCR4-RhoA and PI3K-mTOR signaling axis to reduce motility and proliferation of oral cancer cells.
Zainal NS; Gan CP; Lau BF; Yee PS; Tiong KH; Abdul Rahman ZA; Patel V; Cheong SC
Phytomedicine; 2018 Jan; 39():33-41. PubMed ID: 29433681
[TBL] [Abstract][Full Text] [Related]
18. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antitumor effects of chloroquine on oral squamous cell carcinoma.
Jia L; Wang J; Wu T; Wu J; Ling J; Cheng B
Mol Med Rep; 2017 Nov; 16(5):5779-5786. PubMed ID: 28849182
[TBL] [Abstract][Full Text] [Related]
20. Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway.
Yang J; Ren X; Zhang L; Li Y; Cheng B; Xia J
Biomed Pharmacother; 2018 Apr; 100():226-232. PubMed ID: 29432993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
